disulfiram has been researched along with Disease Models, Animal in 62 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study was to explore the influence of treatment with disulfiram, a small molecule inhibitor to gasdermin D, on the formation and progression of experimental abdominal aortic aneurysms (AAA)." | 8.31 | Pharmacological Inhibition of Gasdermin D Suppresses Angiotensin II-Induced Experimental Abdominal Aortic Aneurysms. ( Ge, Y; Guo, J; Ikezoe, T; Li, Z; Qin, M; Shi, J; Shoji, T; Wang, Y; Xu, B, 2023) |
| "Mouse gouty arthritis model was established by injections of potassium oxonate (PO), monosodium urate (MSU) and pyroptosis suppressor disulfiram." | 8.12 | Pyroptosis inhibition alleviates potassium oxonate- and monosodium urate-induced gouty arthritis in mice. ( Hou, X; Liu, X; Tian, J; Wang, B; Xiang, L; Xie, B; Zhou, D, 2022) |
| "Disulfiram can inhibit inflammation and fibrosis in renal fibrosis rats by inhibiting GSDMD." | 8.02 | Disulfiram inhibits inflammation and fibrosis in a rat unilateral ureteral obstruction model by inhibiting gasdermin D cleavage and pyroptosis. ( Han, X; Zhang, R; Zhang, Y, 2021) |
| "1% hydroxypropylmethylcellulose, and 2% methylcellulose (MC) (DSF eye drops with MC), and tested the ability of a DSF eye drops with MC to reduce intraocular pressure (IOP) in rabbit models." | 7.81 | Effect of Eye Drops Containing Disulfiram and Low-Substituted Methylcellulose in Reducing Intraocular Pressure in Rabbit Models. ( Ito, Y; Mano, Y; Nagai, N; Okamoto, N; Shimomura, Y; Yoshioka, C, 2015) |
| "We attempted to develop anti-cataract eye drops using disulfiram (DSF) and low-substituted methylcellulose (MC), and evaluated their anti-cataract effect in terms of the lens opacification vs." | 7.78 | Pharmacokinetic and pharmacodynamic evaluation of the anti-cataract effect of eye drops containing disulfiram and low-substituted methylcellulose using ICR/f rats as a hereditary cataract model. ( Ito, Y; Nagai, N; Takeuchi, N, 2012) |
| " In this study, we assessed the role of CO donor, methylene chloride (MC), on modulation of lung inflammation during sepsis." | 7.76 | Methylene chloride protects against cecal ligation and puncture-induced acute lung injury by modulating inflammatory mediators. ( Dou, L; He, J; Pan, X; Pang, Q; Xu, W; Zeng, S; Zeng, Y, 2010) |
| "In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety." | 7.74 | Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety. ( Liles, LC; Schank, JR; Weinshenker, D, 2008) |
| "After the induction of colitis with trinitrobenzene sulfonic acid in 64 male rats, physiological saline, honey, prednisolone and disulfiram enemas were applied to the rats once daily for 3 days (acute treatment groups) or 7 days (chronic treatment groups)." | 7.71 | Could honey have a place in colitis therapy? Effects of honey, prednisolone, and disulfiram on inflammation, nitric oxide, and free radical formation. ( Bilsel, Y; Bugra, D; Bulut, T; Cevikbas, U; Turkoglu, U; Yamaner, S, 2002) |
| "In our study we have tried to compare the prophylactic effects of superoxide dismutase (SOD), SOD+catalase (CAT), desferrioxamine, verapamil and disulfiram, which are all free oxygen radical (FOR) scavengers, in an animal model of experimental acetic acid colitis." | 7.69 | The prophylactic effects of superoxide dismutase, catalase, desferrioxamine, verapamil and disulfiram in experimental colitis. ( Cokneşelí, B; Köksoy, FN; Köse, H; Soybír, GR; Yalçin, O, 1997) |
| "Severe acute lung injury has few treatment options and a high mortality rate." | 6.82 | Disulfiram inhibits neutrophil extracellular trap formation and protects rodents from acute lung injury and SARS-CoV-2 infection. ( Adrover, JM; Bram, Y; Carrau, L; Chandar, V; Daßler-Plenker, J; Egeblad, M; Houghton, S; Lyons, SK; Merrill, JR; Redmond, D; Schwartz, RE; Shevik, M; tenOever, BR, 2022) |
| "Glioblastoma is one of the most lethal cancers in humans, and with existing therapy, survival remains at 14." | 5.43 | Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma. ( Aman, A; Cairncross, JG; Dang, NH; Datti, A; Easaw, JC; Grinshtein, N; Hao, X; Kaplan, DR; King, JC; Luchman, A; Lun, X; Robbins, SM; Senger, DL; Uehling, D; Wang, X; Weiss, S; Wells, JC; Wrana, JL, 2016) |
| " This study was to explore the influence of treatment with disulfiram, a small molecule inhibitor to gasdermin D, on the formation and progression of experimental abdominal aortic aneurysms (AAA)." | 4.31 | Pharmacological Inhibition of Gasdermin D Suppresses Angiotensin II-Induced Experimental Abdominal Aortic Aneurysms. ( Ge, Y; Guo, J; Ikezoe, T; Li, Z; Qin, M; Shi, J; Shoji, T; Wang, Y; Xu, B, 2023) |
| "Mouse gouty arthritis model was established by injections of potassium oxonate (PO), monosodium urate (MSU) and pyroptosis suppressor disulfiram." | 4.12 | Pyroptosis inhibition alleviates potassium oxonate- and monosodium urate-induced gouty arthritis in mice. ( Hou, X; Liu, X; Tian, J; Wang, B; Xiang, L; Xie, B; Zhou, D, 2022) |
| "Disulfiram can inhibit inflammation and fibrosis in renal fibrosis rats by inhibiting GSDMD." | 4.02 | Disulfiram inhibits inflammation and fibrosis in a rat unilateral ureteral obstruction model by inhibiting gasdermin D cleavage and pyroptosis. ( Han, X; Zhang, R; Zhang, Y, 2021) |
| "Taken together, disulfiram exhibits all the characteristics required for repurposing as an antibacterial targeting staphylococcal infections." | 3.91 | Repurposing disulfiram for treatment of Staphylococcus aureus infections. ( Chopra, S; Dasgupta, A; Kaul, G; Shukla, M; Thakare, R, 2019) |
| "1% hydroxypropylmethylcellulose, and 2% methylcellulose (MC) (DSF eye drops with MC), and tested the ability of a DSF eye drops with MC to reduce intraocular pressure (IOP) in rabbit models." | 3.81 | Effect of Eye Drops Containing Disulfiram and Low-Substituted Methylcellulose in Reducing Intraocular Pressure in Rabbit Models. ( Ito, Y; Mano, Y; Nagai, N; Okamoto, N; Shimomura, Y; Yoshioka, C, 2015) |
| "Pancreatic cancer cell lines with mutated ras underwent an alternative form of cell death (aponecrosis) when treated concomitantly with clinically achievable concentrations of arsenic trioxide, ascorbic acid, and disulfiram (Antabuse; AAA)." | 3.79 | Redirecting apoptosis to aponecrosis induces selective cytotoxicity to pancreatic cancer cells through increased ROS, decline in ATP levels, and VDAC. ( Brandt-Rauf, P; Cassai, N; Dinnen, RD; Fine, RL; Mao, Y; Nichols, G; Qiu, W; Slavkovich, VN; Su, GH, 2013) |
| "We attempted to develop anti-cataract eye drops using disulfiram (DSF) and low-substituted methylcellulose (MC), and evaluated their anti-cataract effect in terms of the lens opacification vs." | 3.78 | Pharmacokinetic and pharmacodynamic evaluation of the anti-cataract effect of eye drops containing disulfiram and low-substituted methylcellulose using ICR/f rats as a hereditary cataract model. ( Ito, Y; Nagai, N; Takeuchi, N, 2012) |
| " In this study, we assessed the role of CO donor, methylene chloride (MC), on modulation of lung inflammation during sepsis." | 3.76 | Methylene chloride protects against cecal ligation and puncture-induced acute lung injury by modulating inflammatory mediators. ( Dou, L; He, J; Pan, X; Pang, Q; Xu, W; Zeng, S; Zeng, Y, 2010) |
| " Food and Drug Administration (FDA) for use in the treatment of alcohol abuse and alcoholism--disulfiram, naltrexone, and acamprosate." | 3.76 | Pharmacotherapies for alcoholism: the old and the new. ( Olive, MF, 2010) |
| "In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety." | 3.74 | Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety. ( Liles, LC; Schank, JR; Weinshenker, D, 2008) |
| "After the induction of colitis with trinitrobenzene sulfonic acid in 64 male rats, physiological saline, honey, prednisolone and disulfiram enemas were applied to the rats once daily for 3 days (acute treatment groups) or 7 days (chronic treatment groups)." | 3.71 | Could honey have a place in colitis therapy? Effects of honey, prednisolone, and disulfiram on inflammation, nitric oxide, and free radical formation. ( Bilsel, Y; Bugra, D; Bulut, T; Cevikbas, U; Turkoglu, U; Yamaner, S, 2002) |
| "In our study we have tried to compare the prophylactic effects of superoxide dismutase (SOD), SOD+catalase (CAT), desferrioxamine, verapamil and disulfiram, which are all free oxygen radical (FOR) scavengers, in an animal model of experimental acetic acid colitis." | 3.69 | The prophylactic effects of superoxide dismutase, catalase, desferrioxamine, verapamil and disulfiram in experimental colitis. ( Cokneşelí, B; Köksoy, FN; Köse, H; Soybír, GR; Yalçin, O, 1997) |
| "Severe acute lung injury has few treatment options and a high mortality rate." | 2.82 | Disulfiram inhibits neutrophil extracellular trap formation and protects rodents from acute lung injury and SARS-CoV-2 infection. ( Adrover, JM; Bram, Y; Carrau, L; Chandar, V; Daßler-Plenker, J; Egeblad, M; Houghton, S; Lyons, SK; Merrill, JR; Redmond, D; Schwartz, RE; Shevik, M; tenOever, BR, 2022) |
| "Lactoferrin (LF) is a multifunctional glycoprotein with potent antibacterial and anti-inflammatory activities that acts by neutralizing circulating endotoxins and activating cellular responses." | 1.62 | Disulfiram-loaded lactoferrin nanoparticles for treating inflammatory diseases. ( Fang, YF; Huang, YZ; Ou, AT; Tang, XP; Wang, R; Zhang, JX; Zhang, M; Zhao, PF; Zhao, YG, 2021) |
| "Mechanisms underlying scarring are largely unknown in MMP and effective treatment options are limited." | 1.62 | Increased Fibrosis in a Mouse Model of Anti-Laminin 332 Mucous Membrane Pemphigoid Remains Unaltered by Inhibition of Aldehyde Dehydrogenase. ( Boch, K; Brinckmann, J; Busch, H; Chakievska, L; Diel, L; Fähnrich, A; Künzel, S; Patzelt, S; Pigors, M; Schmidt, E; Steenbock, H, 2021) |
| "Prenatal treatment of Down syndrome fetuses is also suggested." | 1.51 | Mental retardation in Down syndrome: Two ways to treat. ( Kamoun, PP, 2019) |
| "Pretreatment of disulfiram in MD model mice increased the copper level in the brain (0." | 1.48 | Disulfiram enhanced delivery of orally administered copper into the central nervous system in Menkes disease mouse model. ( Hamazaki, T; Hoshina, T; Kodama, H; Kudo, S; Nakatani, Y; Nozaki, S; Shintaku, H; Watanabe, Y, 2018) |
| "Pretreatment with disulfiram (5." | 1.48 | Limited modulation of the abuse-related behavioral effects of d-methamphetamine by disulfiram. ( Bergman, J; de Moura, FB; Kohut, SJ, 2018) |
| "Glioblastoma is one of the most lethal cancers in humans, and with existing therapy, survival remains at 14." | 1.43 | Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma. ( Aman, A; Cairncross, JG; Dang, NH; Datti, A; Easaw, JC; Grinshtein, N; Hao, X; Kaplan, DR; King, JC; Luchman, A; Lun, X; Robbins, SM; Senger, DL; Uehling, D; Wang, X; Weiss, S; Wells, JC; Wrana, JL, 2016) |
| " The primary constituent, R-(+)-pulegone, is metabolized via hepatic cytochrome P450 to toxic intermediates." | 1.32 | Mitigation of pennyroyal oil hepatotoxicity in the mouse. ( Bond, GR; Goetz, RJ; Lindsell, CJ; Otten, EJ; Sztajnkrycer, MD, 2003) |
| "Disulfiram has been shown to decrease the incidence of arrhythmias in rabbits exposed to trichloroethylene." | 1.27 | Antiarrhythmic effect of disulfiram in various cardiotoxic models. ( Carlson, GP; Fossa, AA, 1983) |
| "Following chronic administration of disulfiram to rats, changes of the brain were examined electron-microscopically." | 1.26 | Electron microscopic studies on the cerebral lesions of rats in experimental chronic disulfiram poisoning. ( Fujieda, T; Miyagishi, T; Takahata, N; Ueno, T, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (19.35) | 18.7374 |
| 1990's | 6 (9.68) | 18.2507 |
| 2000's | 8 (12.90) | 29.6817 |
| 2010's | 22 (35.48) | 24.3611 |
| 2020's | 14 (22.58) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 2 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Zhang, C | 1 |
| Yue, H | 1 |
| Sun, P | 1 |
| Hua, L | 1 |
| Liang, S | 1 |
| Ou, Y | 1 |
| Wu, D | 1 |
| Wu, X | 1 |
| Chen, H | 1 |
| Hao, Y | 1 |
| Hu, W | 1 |
| Yang, Z | 1 |
| Ou, AT | 1 |
| Zhang, JX | 1 |
| Fang, YF | 1 |
| Wang, R | 1 |
| Tang, XP | 1 |
| Zhao, PF | 1 |
| Zhao, YG | 1 |
| Zhang, M | 1 |
| Huang, YZ | 1 |
| Huang, J | 1 |
| Wei, S | 1 |
| Peng, Z | 1 |
| Xiao, Z | 1 |
| Yang, Y | 1 |
| Liu, J | 1 |
| Zhang, B | 1 |
| Adrover, JM | 1 |
| Carrau, L | 1 |
| Daßler-Plenker, J | 1 |
| Bram, Y | 1 |
| Chandar, V | 1 |
| Houghton, S | 1 |
| Redmond, D | 1 |
| Merrill, JR | 1 |
| Shevik, M | 1 |
| tenOever, BR | 1 |
| Lyons, SK | 1 |
| Schwartz, RE | 1 |
| Egeblad, M | 1 |
| Patzelt, S | 1 |
| Pigors, M | 1 |
| Steenbock, H | 1 |
| Diel, L | 1 |
| Boch, K | 1 |
| Chakievska, L | 1 |
| Künzel, S | 1 |
| Busch, H | 1 |
| Fähnrich, A | 1 |
| Brinckmann, J | 1 |
| Schmidt, E | 1 |
| Liu, C | 1 |
| Tang, J | 1 |
| Liu, S | 1 |
| Shen, C | 1 |
| Zhou, X | 1 |
| Lu, J | 1 |
| Li, M | 1 |
| Zhu, L | 1 |
| Ikebukuro, T | 1 |
| Arima, T | 1 |
| Kasamatsu, M | 1 |
| Nakano, Y | 1 |
| Tobita, Y | 1 |
| Uchiyama, M | 1 |
| Terashima, Y | 1 |
| Toda, E | 1 |
| Shimizu, A | 1 |
| Takahashi, H | 1 |
| Zhou, W | 1 |
| Zhang, H | 1 |
| Huang, L | 1 |
| Sun, C | 1 |
| Yue, Y | 1 |
| Cao, X | 1 |
| Jia, H | 1 |
| Wang, C | 1 |
| Gao, Y | 1 |
| Guo, J | 1 |
| Shi, J | 1 |
| Qin, M | 1 |
| Wang, Y | 1 |
| Li, Z | 1 |
| Shoji, T | 1 |
| Ikezoe, T | 1 |
| Ge, Y | 1 |
| Xu, B | 1 |
| Kamoun, PP | 1 |
| Deguchi, S | 1 |
| Ogata, F | 1 |
| Yamaguchi, M | 1 |
| Minami, M | 1 |
| Otake, H | 1 |
| Kanai, K | 2 |
| Kawasaki, N | 1 |
| Nagai, N | 8 |
| Tian, J | 1 |
| Wang, B | 1 |
| Xie, B | 1 |
| Liu, X | 1 |
| Zhou, D | 1 |
| Hou, X | 1 |
| Xiang, L | 1 |
| Akdaş Reis, Y | 1 |
| Tapisiz, OL | 1 |
| Göktolga, Ü | 1 |
| Şimşek, G | 1 |
| Erten, Ö | 1 |
| Kiykaç Altinbaş, Ş | 1 |
| Erkaya, S | 1 |
| Zhang, Y | 1 |
| Zhang, R | 1 |
| Han, X | 1 |
| de Moura, FB | 1 |
| Kohut, SJ | 1 |
| Bergman, J | 1 |
| Hoshina, T | 1 |
| Nozaki, S | 2 |
| Hamazaki, T | 2 |
| Kudo, S | 2 |
| Nakatani, Y | 1 |
| Kodama, H | 3 |
| Shintaku, H | 2 |
| Watanabe, Y | 2 |
| Das, S | 1 |
| Garg, T | 1 |
| Chopra, S | 2 |
| Dasgupta, A | 2 |
| Thakare, R | 1 |
| Shukla, M | 1 |
| Kaul, G | 1 |
| Contractor, H | 1 |
| Støttrup, NB | 1 |
| Cunnington, C | 1 |
| Manlhiot, C | 1 |
| Diesch, J | 1 |
| Ormerod, JO | 1 |
| Jensen, R | 1 |
| Bøtker, HE | 1 |
| Redington, A | 1 |
| Schmidt, MR | 1 |
| Ashrafian, H | 1 |
| Kharbanda, RK | 1 |
| Ito, Y | 8 |
| Han, J | 1 |
| Liu, L | 1 |
| Yue, X | 1 |
| Chang, J | 1 |
| Shi, W | 1 |
| Hua, Y | 1 |
| Dinnen, RD | 1 |
| Mao, Y | 1 |
| Qiu, W | 1 |
| Cassai, N | 1 |
| Slavkovich, VN | 1 |
| Nichols, G | 1 |
| Su, GH | 1 |
| Brandt-Rauf, P | 1 |
| Fine, RL | 1 |
| Nomura, S | 1 |
| Takeda, T | 1 |
| Ninomiya, E | 1 |
| Hayashinaka, E | 1 |
| Wada, Y | 1 |
| Hiroki, T | 2 |
| Fujisawa, C | 2 |
| Yoshioka, C | 2 |
| Mano, Y | 2 |
| Okamoto, N | 3 |
| Shimomura, Y | 2 |
| Tnabe, W | 1 |
| Lun, X | 1 |
| Wells, JC | 1 |
| Grinshtein, N | 1 |
| King, JC | 1 |
| Hao, X | 1 |
| Dang, NH | 1 |
| Wang, X | 1 |
| Aman, A | 1 |
| Uehling, D | 1 |
| Datti, A | 1 |
| Wrana, JL | 1 |
| Easaw, JC | 1 |
| Luchman, A | 1 |
| Weiss, S | 1 |
| Cairncross, JG | 1 |
| Kaplan, DR | 1 |
| Robbins, SM | 1 |
| Senger, DL | 1 |
| Fernandez Del Ama, L | 1 |
| Jones, M | 1 |
| Walker, P | 1 |
| Chapman, A | 1 |
| Braun, JA | 1 |
| Mohr, J | 1 |
| Hurlstone, AF | 1 |
| Zhao, M | 1 |
| Sun, D | 1 |
| Guan, Y | 1 |
| Wang, Z | 1 |
| Sang, D | 1 |
| Liu, M | 1 |
| Pu, Y | 1 |
| Fang, X | 1 |
| Wang, D | 1 |
| Huang, A | 1 |
| Bi, X | 1 |
| Cao, L | 1 |
| He, C | 1 |
| Celik, O | 1 |
| Ersahin, A | 1 |
| Acet, M | 1 |
| Celik, N | 1 |
| Baykus, Y | 1 |
| Deniz, R | 1 |
| Ozerol, E | 1 |
| Ozerol, I | 1 |
| Murao, T | 1 |
| Olive, MF | 1 |
| Pang, Q | 1 |
| Dou, L | 1 |
| Pan, X | 1 |
| Zeng, S | 1 |
| He, J | 1 |
| Xu, W | 1 |
| Zeng, Y | 1 |
| Itoh, N | 1 |
| Hori, Y | 1 |
| Chikazawa, S | 1 |
| Hoshi, F | 1 |
| Higuchi, S | 1 |
| Takeuchi, N | 1 |
| Bhadhprasit, W | 1 |
| Ogawa, E | 1 |
| Bilsel, Y | 1 |
| Bugra, D | 1 |
| Yamaner, S | 1 |
| Bulut, T | 1 |
| Cevikbas, U | 1 |
| Turkoglu, U | 1 |
| Sztajnkrycer, MD | 1 |
| Otten, EJ | 1 |
| Bond, GR | 1 |
| Lindsell, CJ | 1 |
| Goetz, RJ | 1 |
| Nabekura, T | 1 |
| Tomohiro, M | 1 |
| Kitagawa, S | 1 |
| Heilig, M | 1 |
| Egli, M | 1 |
| Soyka, M | 1 |
| Roesner, S | 1 |
| Schank, JR | 1 |
| Liles, LC | 1 |
| Weinshenker, D | 1 |
| Fossa, AA | 1 |
| Carlson, GP | 1 |
| Wattenberg, LW | 1 |
| Honda, S | 1 |
| Fujioka, T | 1 |
| Shiota, K | 1 |
| Fujiyama, K | 1 |
| Kubota, T | 1 |
| Murakami, K | 1 |
| Nasu, M | 1 |
| Bhadra, S | 1 |
| Prather, PL | 1 |
| Elkhayat, I | 1 |
| Benjamin, D | 1 |
| Harris, CM | 1 |
| Lal, H | 1 |
| Köksoy, FN | 1 |
| Köse, H | 1 |
| Soybír, GR | 1 |
| Yalçin, O | 1 |
| Cokneşelí, B | 1 |
| Hill, DE | 1 |
| Fetterer, RH | 1 |
| Nash, T | 1 |
| Rice, WG | 1 |
| Voll, RE | 1 |
| Mikulowska, A | 1 |
| Kalden, JR | 1 |
| Holmdahl, R | 1 |
| Heros, RC | 1 |
| Zervas, NT | 1 |
| Negoro, M | 1 |
| Zuccarello, M | 1 |
| Anzil, AP | 1 |
| Ueno, T | 1 |
| Miyagishi, T | 1 |
| Takahata, N | 1 |
| Fujieda, T | 1 |
| Arushanian, EB | 1 |
| Sudilovsky, A | 2 |
| Sanny, CG | 1 |
| Mahoney, AJ | 1 |
| Kilmore, MA | 1 |
| Rymas, K | 1 |
| Phillips, SC | 1 |
| Ellinwood, EH | 1 |
| Grabowy, R | 1 |
| Osterholm, JL | 1 |
| Mathews, GJ | 1 |
| Irvin, JD | 1 |
| Calesnick, B | 1 |
| Duvoisin, RC | 1 |
| Marsden, CD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism on Stress-Induced Craving in Alcoholic Women With High Anxiety: an Experimental Medicine Study[NCT01187511] | Phase 2 | 44 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics[NCT01227980] | Phase 2 | 70 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics[NCT00605904] | Phase 2 | 37 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 11.6932 |
| Placebo | 14.6126 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 8.7646 |
| Placebo | 10.413 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 11.4075 |
| Placebo | 13.0412 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 9.6218 |
| Placebo | 12.1841 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 13.9789 |
| Placebo | 15.946 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 9.9075 |
| Placebo | 12.1841 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 9.6218 |
| Placebo | 11.6603 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 8.9075 |
| Placebo | 13.1841 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 12.1376 |
| Placebo | 13.1086 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 9.7805 |
| Placebo | 10.6194 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 11.7091 |
| Placebo | 13.1432 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 11.3519 |
| Placebo | 12.1432 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 14.1376 |
| Placebo | 16.9051 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 11.2805 |
| Placebo | 12.0956 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 12.2091 |
| Placebo | 10.3813 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 13.1376 |
| Placebo | 10.0004 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 100 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 12.977 |
| Placebo | 12.0475 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes prior to the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 15.1645 |
| Placebo | 12.0116 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 20 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 18.4145 |
| Placebo | 15.2497 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 40 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 20.352 |
| Placebo | 18.0116 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 70 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 13.7895 |
| Placebo | 13.0592 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 1 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.8582 |
| Placebo | 8.7076 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 11 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.4777 |
| Placebo | 7.041 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 14 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.5443 |
| Placebo | 6.6122 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 18 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.011 |
| Placebo | 5.4219 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.611 |
| Placebo | 5.7835 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 25 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 5.3112 |
| Placebo | 5.1362 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 28 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.2231 |
| Placebo | 4.5648 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 5.2365 |
| Placebo | 4.2791 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 4 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.6777 |
| Placebo | 5.9457 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 7 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.6078 |
| Placebo | 6.66 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 1 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 10.002 |
| Placebo | 8.7759 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 11 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.3187 |
| Placebo | 6.2997 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 14 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.6521 |
| Placebo | 8.0633 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 18 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 8.0521 |
| Placebo | 6.5855 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.0521 |
| Placebo | 5.9353 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 25 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 4.8092 |
| Placebo | 4.9188 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 28 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.149 |
| Placebo | 4.2997 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 4.8071 |
| Placebo | 4.2045 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 4 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 8.2521 |
| Placebo | 7.1569 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 7 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.6366 |
| Placebo | 6.9188 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 1 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 9.5572 |
| Placebo | 12.2152 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 11 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.7 |
| Placebo | 8.8468 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 14 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 5.7 |
| Placebo | 7.3205 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 18 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.2715 |
| Placebo | 6.9521 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 5.2715 |
| Placebo | 6.531 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 25 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 4.6286 |
| Placebo | 6.6363 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 28 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 3.6083 |
| Placebo | 6.5836 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 3.7666 |
| Placebo | 6.531 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 4 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.9858 |
| Placebo | 9.7942 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 7 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 8.1286 |
| Placebo | 8.7942 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | Units on a scale (Mean) |
|---|---|
| Pexacerfont | 16.6 |
| Placebo | 12.9 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | Units on a scale (Mean) |
|---|---|
| Pexacerfont | 12.7 |
| Placebo | 10.7 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 16.5 |
| Placebo | 11.8 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 15 |
| Placebo | 12.1 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 18.7 |
| Placebo | 14.5 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 13.7 |
| Placebo | 12.3 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 13.5 |
| Placebo | 12 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 13.7 |
| Placebo | 11.7 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 16.8 |
| Placebo | 12.5 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 12.9 |
| Placebo | 10.2 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 15.3 |
| Placebo | 12.2 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 14.9 |
| Placebo | 11.6 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 17.8 |
| Placebo | 14.4 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 14.3 |
| Placebo | 11.6 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 14.9 |
| Placebo | 11.7 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | Units on a scale (Mean) |
|---|---|
| Pexacerfont | 14.6 |
| Placebo | 11.2 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving. (NCT00605904)
Timeframe: 180 minutes after the start of the infusion
| Intervention | Units on a scale (Mean) |
|---|---|
| Acamprosate | 3.460 |
| Placebo | 5.416 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving. (NCT00605904)
Timeframe: 180 minutes after the start of the infusion
| Intervention | Units on a scale (Mean) |
|---|---|
| Acamprosate | 1.704 |
| Placebo | 1.766 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving. (NCT00605904)
Timeframe: 180 minutes after the start of the infusion
| Intervention | Units on a scale (Mean) |
|---|---|
| Acamprosate | 3.613 |
| Placebo | 3.606 |
5 reviews available for disulfiram and Disease Models, Animal
| Article | Year |
|---|---|
Disulfiram inhibits neutrophil extracellular trap formation and protects rodents from acute lung injury and SARS-CoV-2 infection.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Acute Lung Injury; Animals; COVID-19; Disease Models, Animal; | 2022 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
New pharmacological approaches for the treatment of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Carbamazepine; Depression; Disease Models, Ani | 2006 |
Inhibition of chemical carcinogenesis by antioxidants.
Topics: Animals; Antioxidants; Butylated Hydroxyanisole; Butylated Hydroxytoluene; Carcinogens; Cysteamine; | 1980 |
Cerebral vasospasm.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin II; Animals; Blood Platelets; | 1976 |
1 trial available for disulfiram and Disease Models, Animal
| Article | Year |
|---|---|
Aldehyde dehydrogenase-2 inhibition blocks remote preconditioning in experimental and human models.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; Analysis of Variance; Animals; Cross- | 2013 |
56 other studies available for disulfiram and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Discovery of chalcone analogues as novel NLRP3 inflammasome inhibitors with potent anti-inflammation activities.
Topics: Animals; Anti-Inflammatory Agents; Cell Line; Chalcones; Colitis; Disease Models, Animal; Drug Desig | 2021 |
Disulfiram-loaded lactoferrin nanoparticles for treating inflammatory diseases.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Animals; Anti-Inflammatory Agents; Biomimetic Materials; Coli | 2021 |
Disulfiram attenuates lipopolysaccharide-induced acute kidney injury by suppressing oxidative stress and NLRP3 inflammasome activation in mice.
Topics: Acute Kidney Injury; Animals; Apoptosis; Blood Urea Nitrogen; Creatinine; Disease Models, Animal; Di | 2022 |
Increased Fibrosis in a Mouse Model of Anti-Laminin 332 Mucous Membrane Pemphigoid Remains Unaltered by Inhibition of Aldehyde Dehydrogenase.
Topics: Aldehyde Dehydrogenase; Animals; Autoimmune Diseases; Cicatrix; Collagen; Disease Models, Animal; Di | 2021 |
Cathepsin B/NLRP3/GSDMD axis-mediated macrophage pyroptosis induces inflammation and fibrosis in systemic sclerosis.
Topics: Animals; Caspase 1; Cathepsin B; Disease Models, Animal; Disulfiram; Fibrosis; Humans; Inflammasomes | 2022 |
Disulfiram Ophthalmic Solution Inhibited Macrophage Infiltration by Suppressing Macrophage Pseudopodia Formation in a Rat Corneal Alkali Burn Model.
Topics: Alkalies; Animals; Burns, Chemical; Cornea; Corneal Injuries; Corneal Neovascularization; Disease Mo | 2023 |
Disulfiram with Cu
Topics: Animals; Anti-Inflammatory Agents; Colitis; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Mod | 2023 |
Pharmacological Inhibition of Gasdermin D Suppresses Angiotensin II-Induced Experimental Abdominal Aortic Aneurysms.
Topics: Angiotensin II; Animals; Aortic Aneurysm, Abdominal; Body Weight; Disease Models, Animal; Disulfiram | 2023 |
Mental retardation in Down syndrome: Two ways to treat.
Topics: Aminooxyacetic Acid; Animals; Benserazide; Brain; Chromosomes, Human, Pair 21; Cobamides; Cystathion | 2019 |
In Situ Gel Incorporating Disulfiram Nanoparticles Rescues the Retinal Dysfunction via ATP Collapse in Otsuka Long-Evans Tokushima Fatty Rats.
Topics: Adenosine Triphosphate; Animals; Diabetic Retinopathy; Disease Models, Animal; Disulfiram; Gels; Hum | 2020 |
Pyroptosis inhibition alleviates potassium oxonate- and monosodium urate-induced gouty arthritis in mice.
Topics: Animals; Arthritis, Gouty; Creatinine; Cytokines; Disease Models, Animal; Disulfiram; Humans; Mice; | 2022 |
The Effect of Disulfiram in the Prevention of Postoperative Adhesion Formation in an Experimental Rat Uterine Horn Model.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Disulfiram; Drug Ad | 2021 |
Disulfiram inhibits inflammation and fibrosis in a rat unilateral ureteral obstruction model by inhibiting gasdermin D cleavage and pyroptosis.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Cell Line; Cell Survival; Disease Models, Animal; Disu | 2021 |
Limited modulation of the abuse-related behavioral effects of d-methamphetamine by disulfiram.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Amphetamine-Related Disorders; Animals; Behavioral Symptoms; | 2018 |
Disulfiram enhanced delivery of orally administered copper into the central nervous system in Menkes disease mouse model.
Topics: Animals; Autoradiography; Blood-Brain Barrier; Copper; Disease Models, Animal; Disulfiram; Drug Carr | 2018 |
Repurposing disulfiram to target infections caused by non-tuberculous mycobacteria.
Topics: Animals; Anti-Bacterial Agents; Chlorocebus aethiops; Colony Count, Microbial; Disease Models, Anima | 2019 |
Repurposing disulfiram for treatment of Staphylococcus aureus infections.
Topics: Alcohol Deterrents; Animals; Anti-Bacterial Agents; Chlorocebus aethiops; Disease Models, Animal; Di | 2019 |
Excessive hydrogen peroxide enhances the attachment of amyloid β1-42 in the lens epithelium of UPL rats, a hereditary model for cataracts.
Topics: Age Factors; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secret | 2014 |
A binuclear complex constituted by diethyldithiocarbamate and copper(I) functions as a proteasome activity inhibitor in pancreatic cancer cultures and xenografts.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Cop | 2013 |
Redirecting apoptosis to aponecrosis induces selective cytotoxicity to pancreatic cancer cells through increased ROS, decline in ATP levels, and VDAC.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Asc | 2013 |
PET imaging analysis with 64Cu in disulfiram treatment for aberrant copper biodistribution in Menkes disease mouse model.
Topics: Animals; Autoradiography; Brain; Chelating Agents; Copper; Copper Radioisotopes; Disease Models, Ani | 2014 |
Effect of Eye Drops Containing Disulfiram and Low-Substituted Methylcellulose in Reducing Intraocular Pressure in Rabbit Models.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Administration, Topical; Alcohol Deterrents; Animals; Aqueous Hum | 2015 |
A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure.
Topics: Animals; Cornea; Disease Models, Animal; Disulfiram; Drug Delivery Systems; Escherichia coli; Free R | 2015 |
Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Copper; Dacarbazine; Disease Mode | 2016 |
Reprofiling using a zebrafish melanoma model reveals drugs cooperating with targeted therapeutics.
Topics: Abietanes; Animals; Animals, Genetically Modified; Apoptosis; Benzamides; Cell Line, Tumor; Disease | 2016 |
Disulfiram and Diphenhydramine Hydrochloride Upregulate miR-30a to Suppress IL-17-Associated Autoimmune Inflammation.
Topics: Animals; Case-Control Studies; Cell Differentiation; Cells, Cultured; Diphenhydramine; Disease Model | 2016 |
Disulfiram, as a candidate NF-κB and proteasome inhibitor, prevents endometriotic implant growing in a rat model of endometriosis.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Animals; Disease Models, Animal; Disulfiram; Endometriosis; F | 2016 |
Disulfiram reduces elevated blood glucose levels in Otsuka Long-Evans Tokushima Fatty (OLETF) rats, a model of type 2 diabetes.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Disulfiram; | 2009 |
Pharmacotherapies for alcoholism: the old and the new.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Induced Disorders, Nervous System; Alcoholism; Animals; Dis | 2010 |
Methylene chloride protects against cecal ligation and puncture-induced acute lung injury by modulating inflammatory mediators.
Topics: Acute Lung Injury; Animals; Carbon Monoxide; Cecum; Cytoprotection; Disease Models, Animal; Disulfir | 2010 |
Effects of instillation of eyedrops containing disulfiram and hydroxypropyl-β-cyclodextrin inclusion complex on endotoxin-induced uveitis in rats.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Anti-Inflammatory Agents; Aqueous Humor; beta-Cyclodextr | 2012 |
Pharmacokinetic and pharmacodynamic evaluation of the anti-cataract effect of eye drops containing disulfiram and low-substituted methylcellulose using ICR/f rats as a hereditary cataract model.
Topics: Animals; Antioxidants; Cataract; Disease Models, Animal; Disulfiram; Drug Carriers; Hypromellose Der | 2012 |
Effect of copper and disulfiram combination therapy on the macular mouse, a model of Menkes disease.
Topics: Animals; Blood-Brain Barrier; Copper; Disease Models, Animal; Disulfiram; Electron Transport Complex | 2012 |
Could honey have a place in colitis therapy? Effects of honey, prednisolone, and disulfiram on inflammation, nitric oxide, and free radical formation.
Topics: Animals; Anti-Inflammatory Agents; Colitis; Disease Models, Animal; Disulfiram; Enzyme Inhibitors; H | 2002 |
Mitigation of pennyroyal oil hepatotoxicity in the mouse.
Topics: Animals; Case-Control Studies; Cimetidine; Cyclohexane Monoterpenes; Cyclohexanones; Disease Models, | 2003 |
Changes in plasma membrane Ca2+ -ATPase expression and ATP content in lenses of hereditary cataract UPL rats.
Topics: Adenosine Triphosphate; Animals; Calcium-Transporting ATPases; Cataract; Cell Membrane; Disease Mode | 2004 |
Adverse effects of excessive nitric oxide on cytochrome c oxidase in lenses of hereditary cataract UPL rats.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Cataract; Disease Models, Animal; Disulfiram; | 2007 |
Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety.
Topics: Adrenergic beta-Antagonists; Animals; Anxiety; Behavior, Animal; Cocaine; Disease Models, Animal; Di | 2008 |
Antiarrhythmic effect of disulfiram in various cardiotoxic models.
Topics: Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Disulfiram; Heart Diseases; Male; Myocardia | 1983 |
Effects of ethanol on the pancreas of disulfiram-treated rats.
Topics: Acetaldehyde; Acute Disease; Administration, Oral; Amylases; Animals; Disease Models, Animal; Disulf | 1995 |
Anxiogenic effect of disulfiram evaluated in an animal model.
Topics: Acetaldehyde; Animals; Appetitive Behavior; Arousal; Conditioning, Operant; Discrimination Learning; | 1993 |
The prophylactic effects of superoxide dismutase, catalase, desferrioxamine, verapamil and disulfiram in experimental colitis.
Topics: Acetic Acid; Animals; Calcium Channel Blockers; Catalase; Colitis; Colonic Diseases; Deferoxamine; D | 1997 |
The effect of disulfiram on egg shell formation in adult Trichuris muris.
Topics: Administration, Oral; Animals; Disease Models, Animal; Disulfiram; Dose-Response Relationship, Drug; | 1997 |
Efficacies of zinc-finger-active drugs against Giardia lamblia.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Disulfiram; Drug Evaluation, Preclinical; Gia | 1998 |
Amelioration of type II collagen induced arthritis in rats by treatment with sodium diethyldithiocarbamate.
Topics: Animals; Arthritis, Rheumatoid; Collagen; Disease Models, Animal; Disulfiram; Ditiocarb; Drug Admini | 1999 |
A localized model of experimental neuropathy by topical application of disulfiram.
Topics: Animals; Disease Models, Animal; Disulfiram; Male; Peripheral Nervous System Diseases; Rats; Sciatic | 1979 |
Electron microscopic studies on the cerebral lesions of rats in experimental chronic disulfiram poisoning.
Topics: Animals; Brain; Capillaries; Cerebral Cortex; Chronic Disease; Disease Models, Animal; Disulfiram; H | 1977 |
[The phenomenon of experimental motor retardation as one of the manifestations of the Parkinsonian syndrome].
Topics: Amphetamine; Animals; Catecholamines; Cats; Caudate Nucleus; Chlorpromazine; Dihydroergotoxine; Dise | 1975 |
Effects of disulfiram on the amphetamine-induced behavioral syndrome in the cat as a model of psychosis.
Topics: Animals; Behavior, Animal; Cats; Disease Models, Animal; Disulfiram; Drug Interactions; Female; Huma | 1975 |
Effect of disulfiram on canine liver aldehyde dehydrogenase activity: in vivo inactivation in a nonrodent animal model.
Topics: Aldehyde Dehydrogenase; Animals; Disease Models, Animal; Disulfiram; Dogs; Dose-Response Relationshi | 1988 |
Can brain lesions occur in experimental animals by administration of ethanol or acetaldehyde?
Topics: Acetaldehyde; Administration, Inhalation; Alcoholism; Animals; Brain; Disease Models, Animal; Disulf | 1987 |
Olfactory forebrain seizures induced by methamphetamine and disulfiram.
Topics: Amphetamine; Animals; Brain; Brain Chemistry; Cats; Disease Models, Animal; Disulfiram; Dopamine; El | 1973 |
Chapter 29. Anti-norepinephrine therapy against traumatic hemorrhagic necrosis of the spinal cord: preliminary report.
Topics: Animals; Bretylium Compounds; Cats; Dihydroxyphenylalanine; Disease Models, Animal; Disulfiram; Guan | 1973 |
Reversal of reserpine-induced bradykinesia by alpha-methyldopa--new light on its modus operandi.
Topics: Animals; Carbidopa; Chlorpromazine; Dihydroxyphenylalanine; Disease Models, Animal; Disulfiram; Dose | 1974 |